ImmunityBio Stock Maintains Golden Cross Signal
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy IBRX?
Source: Benzinga
- Golden Cross Signal: ImmunityBio's stock is currently trading at approximately $8.04, which is about 170% above its 200-day moving average of $2.95, indicating sustained long-term trend strength and increased investor confidence in the stock.
- Trend Support Levels: The stock is now above all major moving averages, trading about 24% above the 20-day moving average of $6.90 and roughly 91% above the 50-day moving average of $4.21, demonstrating strong price performance across multiple timeframes and reinforcing its upward trend.
- Momentum Indicators Confirmed: ImmunityBio's average daily trading volume has risen to approximately 1.7 million shares, reflecting increased market participation, while the Relative Strength Index (RSI) is near 67, indicating strong upward momentum without reaching the overbought threshold of 70, suggesting sustained buying pressure.
- Golden Cross Structure Intact: The 50-day moving average stands at $4.21, approximately 42% above the 200-day moving average, confirming the persistence of the Golden Cross structure, with prices holding well above the 200-day level, indicating that ImmunityBio maintains a technically confirmed long-term uptrend.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.540
Low
5.00
Averages
7.33
High
9.00
Current: 8.540
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio Establishes Irish Subsidiary and Expands Anktiva Distribution
- New Subsidiary Established: ImmunityBio announced the formation of a new Irish subsidiary to support the distribution and commercialization strategy of its bladder cancer therapy, Anktiva, marking a significant expansion in the European market.
- Distribution Agreement Signed: The distribution deal with Accord Healthcare will leverage over 100 sales, medical, and marketing professionals to drive Anktiva's market penetration in the U.K. and Europe, which is expected to significantly enhance product acceptance.
- Regulatory Approval Secured: Anktiva recently received conditional marketing authorization from the European Commission, allowing its use as part of a combination regimen for specific bladder cancer patients in Europe, further enhancing the product's market potential.
- Positive Market Reaction: Following the approval, ImmunityBio's stock price rose, reflecting investor optimism about the new therapy's prospects, while also leading to short sellers facing paper losses of up to $492 million.
See More
ImmunityBio Secures Conditional EU Authorization for Anktiva
- Conditional EU Authorization: ImmunityBio's Anktiva has received conditional marketing authorization from the European Commission, allowing sales across 27 EU member states, Iceland, Liechtenstein, and Norway, marking a significant expansion in the global market.
- Safety and Efficacy Data Submission: The company will submit long-term safety and efficacy data to the European Medicines Agency to meet regulatory requirements and facilitate the widespread use of Anktiva in Europe, addressing the treatment gap for BCG-unresponsive NMIBC CIS patients.
- Positive Market Reaction: Following the authorization, ImmunityBio's stock surged 30% on Wednesday, reflecting strong market demand for the new therapy and investor optimism, indicating the company's potential in treating BCG-unresponsive bladder cancer.
- Global Approval Progress: Anktiva is now approved in 33 countries, including the U.S., showcasing the company's regulatory success within just two years, with CEO Richard Adcock highlighting the strength of clinical evidence and the urgency of unmet market needs.
See More
ImmunityBio Stock Maintains Golden Cross Signal
- Golden Cross Signal: ImmunityBio's stock is currently trading at approximately $8.04, which is about 170% above its 200-day moving average of $2.95, indicating sustained long-term trend strength and increased investor confidence in the stock.
- Trend Support Levels: The stock is now above all major moving averages, trading about 24% above the 20-day moving average of $6.90 and roughly 91% above the 50-day moving average of $4.21, demonstrating strong price performance across multiple timeframes and reinforcing its upward trend.
- Momentum Indicators Confirmed: ImmunityBio's average daily trading volume has risen to approximately 1.7 million shares, reflecting increased market participation, while the Relative Strength Index (RSI) is near 67, indicating strong upward momentum without reaching the overbought threshold of 70, suggesting sustained buying pressure.
- Golden Cross Structure Intact: The 50-day moving average stands at $4.21, approximately 42% above the 200-day moving average, confirming the persistence of the Golden Cross structure, with prices holding well above the 200-day level, indicating that ImmunityBio maintains a technically confirmed long-term uptrend.
See More
ImmunityBio Partners with Accord Healthcare to Expand Anktiva Access
- Partnership Expansion: ImmunityBio has partnered with Accord Healthcare to expand access to Anktiva across 30 countries, aiming to enhance market share and sales potential through increased market coverage.
- European Strategic Setup: The establishment of an Irish subsidiary in Dublin will support ImmunityBio's distribution and commercialization strategy in Europe, helping to optimize supply chains and enhance competitiveness in the European market.
- Stock Price Fluctuation: ImmunityBio shares fell approximately 8% in Thursday's opening trade, indicating that the market's initial reaction to the partnership news may not have met expectations, impacting investor sentiment.
- Market Sentiment: Despite the stock price decline, retail investor sentiment on Stocktwits remains in the 'bullish' territory, reflecting some investors' confidence in the company's future growth potential, which could influence subsequent market performance.
See More
Investors Focus on Fed Minutes and Walmart Earnings
- Fed Minutes Analysis: The January FOMC minutes indicate broad support among policymakers for pausing rate cuts despite ongoing inflation risks, which could influence future monetary policy directions and affect market sentiment and investment decisions.
- Walmart Earnings Preview: Walmart is set to report earnings before the bell today, with investors keenly awaiting insights from the new CEO regarding consumer health and demand, which will directly impact retail sector performance and investor confidence.
- Meta Smartwatch Plans Revived: Reports suggest that Meta has revived its smartwatch plans targeting a launch this year, a strategic shift that could enhance its competitiveness in the wearables market and provide new revenue streams for the company.
- Economic Data and Market Reaction: Key economic indicators such as Initial Jobless Claims and the Philly Fed Business Index are scheduled for release today, with investors closely monitoring their impact on the market, especially amid heightened uncertainty regarding Fed policies.
See More
ImmunityBio's Short Interest Turns Bullish Ahead of EU Decision
- Record Short Interest: Between February 13 and 19, ImmunityBio's short interest surged to 13.7% of free float, marking an all-time high and increasing from 12.9% in the previous period, indicating heightened investor anxiety ahead of the European Commission's decision on Anktiva.
- Retail Sentiment Shift: During the same timeframe, retail traders flipped from 'bearish' to 'bullish', with Stocktwits message volume jumping over 300%, reflecting optimism about potential European approval and suggesting that short sellers could be caught off guard.
- Surge in Options Activity: On February 18, over 30,000 call options were traded for ImmunityBio, nearly double the normal volume, while implied volatility rose to around 129%, indicating strong market expectations for the company's future performance following the anticipated regulatory decision.
- EU Approval Boosts Stock Price: Following the European Commission's conditional marketing authorization, ImmunityBio's shares soared 42%, expanding Anktiva's availability to 33 countries, which signifies a major breakthrough for the company in the cancer treatment landscape.
See More
ImmunityBio Establishes Irish Subsidiary and Expands Anktiva Distribution
- New Subsidiary Established: ImmunityBio announced the formation of a new Irish subsidiary to support the distribution and commercialization strategy of its bladder cancer therapy, Anktiva, marking a significant expansion in the European market.
- Distribution Agreement Signed: The distribution deal with Accord Healthcare will leverage over 100 sales, medical, and marketing professionals to drive Anktiva's market penetration in the U.K. and Europe, which is expected to significantly enhance product acceptance.
- Regulatory Approval Secured: Anktiva recently received conditional marketing authorization from the European Commission, allowing its use as part of a combination regimen for specific bladder cancer patients in Europe, further enhancing the product's market potential.
- Positive Market Reaction: Following the approval, ImmunityBio's stock price rose, reflecting investor optimism about the new therapy's prospects, while also leading to short sellers facing paper losses of up to $492 million.
See More
ImmunityBio Secures Conditional EU Authorization for Anktiva
- Conditional EU Authorization: ImmunityBio's Anktiva has received conditional marketing authorization from the European Commission, allowing sales across 27 EU member states, Iceland, Liechtenstein, and Norway, marking a significant expansion in the global market.
- Safety and Efficacy Data Submission: The company will submit long-term safety and efficacy data to the European Medicines Agency to meet regulatory requirements and facilitate the widespread use of Anktiva in Europe, addressing the treatment gap for BCG-unresponsive NMIBC CIS patients.
- Positive Market Reaction: Following the authorization, ImmunityBio's stock surged 30% on Wednesday, reflecting strong market demand for the new therapy and investor optimism, indicating the company's potential in treating BCG-unresponsive bladder cancer.
- Global Approval Progress: Anktiva is now approved in 33 countries, including the U.S., showcasing the company's regulatory success within just two years, with CEO Richard Adcock highlighting the strength of clinical evidence and the urgency of unmet market needs.
See More
ImmunityBio Stock Maintains Golden Cross Signal
- Golden Cross Signal: ImmunityBio's stock is currently trading at approximately $8.04, which is about 170% above its 200-day moving average of $2.95, indicating sustained long-term trend strength and increased investor confidence in the stock.
- Trend Support Levels: The stock is now above all major moving averages, trading about 24% above the 20-day moving average of $6.90 and roughly 91% above the 50-day moving average of $4.21, demonstrating strong price performance across multiple timeframes and reinforcing its upward trend.
- Momentum Indicators Confirmed: ImmunityBio's average daily trading volume has risen to approximately 1.7 million shares, reflecting increased market participation, while the Relative Strength Index (RSI) is near 67, indicating strong upward momentum without reaching the overbought threshold of 70, suggesting sustained buying pressure.
- Golden Cross Structure Intact: The 50-day moving average stands at $4.21, approximately 42% above the 200-day moving average, confirming the persistence of the Golden Cross structure, with prices holding well above the 200-day level, indicating that ImmunityBio maintains a technically confirmed long-term uptrend.
See More
ImmunityBio Partners with Accord Healthcare to Expand Anktiva Access
- Partnership Expansion: ImmunityBio has partnered with Accord Healthcare to expand access to Anktiva across 30 countries, aiming to enhance market share and sales potential through increased market coverage.
- European Strategic Setup: The establishment of an Irish subsidiary in Dublin will support ImmunityBio's distribution and commercialization strategy in Europe, helping to optimize supply chains and enhance competitiveness in the European market.
- Stock Price Fluctuation: ImmunityBio shares fell approximately 8% in Thursday's opening trade, indicating that the market's initial reaction to the partnership news may not have met expectations, impacting investor sentiment.
- Market Sentiment: Despite the stock price decline, retail investor sentiment on Stocktwits remains in the 'bullish' territory, reflecting some investors' confidence in the company's future growth potential, which could influence subsequent market performance.
See More
Investors Focus on Fed Minutes and Walmart Earnings
- Fed Minutes Analysis: The January FOMC minutes indicate broad support among policymakers for pausing rate cuts despite ongoing inflation risks, which could influence future monetary policy directions and affect market sentiment and investment decisions.
- Walmart Earnings Preview: Walmart is set to report earnings before the bell today, with investors keenly awaiting insights from the new CEO regarding consumer health and demand, which will directly impact retail sector performance and investor confidence.
- Meta Smartwatch Plans Revived: Reports suggest that Meta has revived its smartwatch plans targeting a launch this year, a strategic shift that could enhance its competitiveness in the wearables market and provide new revenue streams for the company.
- Economic Data and Market Reaction: Key economic indicators such as Initial Jobless Claims and the Philly Fed Business Index are scheduled for release today, with investors closely monitoring their impact on the market, especially amid heightened uncertainty regarding Fed policies.
See More
ImmunityBio's Short Interest Turns Bullish Ahead of EU Decision
- Record Short Interest: Between February 13 and 19, ImmunityBio's short interest surged to 13.7% of free float, marking an all-time high and increasing from 12.9% in the previous period, indicating heightened investor anxiety ahead of the European Commission's decision on Anktiva.
- Retail Sentiment Shift: During the same timeframe, retail traders flipped from 'bearish' to 'bullish', with Stocktwits message volume jumping over 300%, reflecting optimism about potential European approval and suggesting that short sellers could be caught off guard.
- Surge in Options Activity: On February 18, over 30,000 call options were traded for ImmunityBio, nearly double the normal volume, while implied volatility rose to around 129%, indicating strong market expectations for the company's future performance following the anticipated regulatory decision.
- EU Approval Boosts Stock Price: Following the European Commission's conditional marketing authorization, ImmunityBio's shares soared 42%, expanding Anktiva's availability to 33 countries, which signifies a major breakthrough for the company in the cancer treatment landscape.
See More
